Related references
Note: Only part of the references are listed.Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
Christos C. Zouboulis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis
Mohammed I. Aladul et al.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2019)
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Sizheng Zhao et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Roy M. Fleischmann et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
Jan Hillson et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
Laurent Magnenat et al.
MABS (2017)
Biosimilars in rheumatology: understanding the rigor of their development
Niti Goel et al.
RHEUMATOLOGY (2017)
A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis
Salvatore Bellinvia et al.
IMMUNOTHERAPY (2017)
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
Changsoo Lee et al.
MABS (2017)
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
Joachim R. Kalden et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
Hendrik Schulze-Koops et al.
RHEUMATOLOGY (2017)
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Till Uhlig et al.
RHEUMATOLOGY (2017)
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials
John Sheppard et al.
JAMA OPHTHALMOLOGY (2017)
Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy
Valeria Rios Rodriguez et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2017)
Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK
Mohammed I. Aladul et al.
BIODRUGS (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
Alan Menter et al.
DERMATOLOGY AND THERAPY (2017)
Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
Adeep Puri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study
Yago Gonzalez-Lama et al.
JOURNAL OF CROHNS & COLITIS (2016)
The changing landscape of biosimilars in rheumatology
Thomas Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
Ira Jacobs et al.
BIODRUGS (2016)
Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects
Elizabeth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B. Kimball et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
Zhihong Lai et al.
RMD OPEN (2016)
Humira: the impending patent battles over adalimumab biosimilars
Peter Norman
PHARMACEUTICAL PATENT ANALYST (2016)
Biosimilars in rheumatology: current perspectives and lessons learnt
Thomas Doerner et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis
Enayatullah Baki et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
Philip Mease et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Etanercept biosimilars
Valderilio F. Azevedo et al.
RHEUMATOLOGY INTERNATIONAL (2015)
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper
Gionata Fiorino et al.
AUTOIMMUNITY REVIEWS (2014)
ANTI-TNF AGENTS AS THERAPEUTIC CHOICE IN IMMUNE-MEDIATED INFLAMMATORY DISEASES: FOCUS ON ADALIMUMAB
A. Armuzzi et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2014)
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Biosimilars to treat inflammatory arthritis: the challenge of proving identity
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adalimumab in active ulcerative colitis: A real-life observational study
Alessandro Armuzzi et al.
DIGESTIVE AND LIVER DISEASE (2013)
Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
Shi Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2013)
Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study
Stefan Kleinert et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry
Merete Lund Hetland et al.
ARTHRITIS AND RHEUMATISM (2010)
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
Zehra Kaymakcalan et al.
CLINICAL IMMUNOLOGY (2009)
ASHO position paper on Biosimilars
G. Gastl et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2009)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
Daniel J. Lovell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The British Society for Rheumatology biologics register: 6 years on
K. L. Hyrich et al.
RHEUMATOLOGY (2008)
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J. -H. Saurat et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data
W. Kievit et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice:: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Annabel Kuek et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
PJ Anderson
SEMINARS IN ARTHRITIS AND RHEUMATISM (2005)
Advances in immunology - Autoimmune diseases
A Davidson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
